Millennium's Dunsire named HBA Woman of the Year

Share this article:
Deborah Dunsire
Deborah Dunsire
The Healthcare Businesswomen's Association named Millennium chief Dr. Deborah Dunsire as its 2009 Woman of the Year.

Dr. Dunsire, who is president and CEO of Millennium: The Takeda Oncology Company, presided over the company's acquisition by Takeda last May. She joined Millennium in 2005 after nearly 10 years at Novartis, most recently as head of North American Oncology. Before that, she was at Sandoz, where she got her start in the industry.

“Her contributions to the health sciences and improving patient lives in oncology is something all of us would like to emulate in our own careers,” said HBA president and VP of marketing at Sanofi-Aventis Ceci Zak, who also hailed Dunsire's support of HBA.

“Deborah's distinctive leadership has had an incomparable impact on Millennium and all of its employees,” said Yasuchika Hasegawa, president, Takeda Pharmaceutical Co. Ltd., in a statement. “Deborah brings great energy and passion to her role, and her goal to improve the lives of cancer patients is at the forefront of everything she does.”

Dunsire was previously named an HBA Rising Star and has spoken at the group's annual leadership conference. She serves on the boards of the Biotechnology Industry Organization, Allergan and CancerCare, among others. She served as a judge for the 2008 MM&M Awards.

She will be honored at the HBA's 20th Annual Woman of the Year luncheon in New York on May 7.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...